Vertex Pharmaceuticals Aktie 983327 / US92532F1003
451.24
USD
3.26
USD
0.73%
20.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Vertex Pharmaceuticals Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2022 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2021 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2020 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2019 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2018 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2017 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2016 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2015 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2014 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Vertex Pharmaceuticals
| 1.0 17 | 8.1 18 | 4.5 19 | 10.3 20 | 9.0 21 | 12.8 22 | 13.9 23 |
Umsatz je Aktie- Vertex Pharmaceuticals
| 9.8 17 | 11.8 18 | 15.8 19 | 23.6 20 | 29.3 21 | 33.8 22 | 37.8 23 |
KGV- Vertex Pharmaceuticals
| 144 17 | 20.5 18 | 48.5 19 | 23.0 20 | 24.4 21 | 22.5 22 | 29.3 23 |
Vertex Pharmaceuticals Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 |
| Gewinn je Aktie unverwässert | 1.06 | 8.24 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 |
| Gewinn je Aktie verwässert | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Vertex Pharmaceuticals Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 9.83 | 11.76 | 15.84 | 23.57 | 29.26 | 33.76 | 37.77 |
| KGV (Jahresendkurs, EPS unverwässert) | 144.10 | 20.48 | 48.50 | 22.96 | 24.37 | 22.52 | 29.28 |
| KGV (Jahresendkurs, EPS verwässert) | 144.10 | 20.48 | 48.50 | 22.96 | 24.37 | 22.52 | 29.28 |
| KGV (Jahresendkurs) | 144.10 | 20.48 | 48.50 | 22.96 | 24.37 | 22.52 | 29.28 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 57.59 | 71.01 | 73.15 | 73.92 | 75.19 | 76.65 | 76.15 |
| Fremdkapitalquote in % | 42.41 | 28.99 | 26.85 | 26.08 | 24.81 | 23.35 | 23.85 |
Vertex Pharmaceuticals Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 2’488.65 | 3’048.85 | 4’130.28 | 6’209.40 | 7’604.40 | 8’748.20 | 9’839.00 |
| Umsatzveränderung in % | 46.20 | 22.51 | 35.47 | 50.34 | 22.47 | 15.04 | 12.47 |
| Bruttoergebnis vom Umsatz | 2’213.53 | 2’639.31 | 3’582.52 | 5’473.10 | 6’700.20 | 7’667.90 | 8’576.80 |
| Bruttoergebnisveränderung in % | 48.39 | 19.24 | 35.74 | 52.77 | 22.42 | 14.44 | 11.85 |
| Operatives Ergebnis | 397.93 | 665.22 | 1’169.48 | 2’873.10 | 2’809.00 | 4’080.40 | 4’277.30 |
| Veränderung Operatives Ergebnis in % | 3’453.57 | 67.17 | 75.80 | 145.67 | -2.23 | 45.26 | 4.83 |
| Ergebnis vor Steuern | -15.69 | 600.24 | 1’394.92 | 3’116.80 | 2’730.40 | 4’232.40 | 4’379.80 |
| Veränderung Ergebnis vor Steuern in % | 76.71 | - | 132.39 | 123.44 | -12.40 | 55.01 | 3.48 |
| Ergebnis nach Steuer | 263.19 | 2’096.40 | 1’176.81 | 2’711.65 | 2’342.10 | 3’322.00 | 3’619.60 |
| Veränderung Ergebnis nach Steuer in % | - | 696.53 | -43.87 | 130.42 | -13.63 | 41.84 | 8.96 |
Vertex Pharmaceuticals Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 1’504 | 1’811 | 2’233 | 3’065 | 3’333 | 4’238 | 5’506 |
| Langzeit Gesamtverbindlichk. pro Aktie | 2.75 | 2.71 | 3.47 | 4.57 | 4.68 | 5.82 | 7.60 |
| Eigenkapital | 2’042 | 4’435 | 6’085 | 8’687 | 10’100 | 13’913 | 17’580 |
| Veränderung Eigenkapital in % | 75.39 | 118.64 | 37.20 | 42.75 | 16.27 | 37.75 | 26.36 |
| Bilanzsumme | 3’546 | 6’246 | 8’318 | 11’752 | 13’433 | 18’151 | 23’086 |
| Veränderung Bilanzsumme in % | 22.41 | 76.14 | 33.18 | 41.27 | 14.30 | 35.13 | 27.19 |
Vertex Pharmaceuticals Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.06 | 8.24 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 |
| Veränderung Gewinn je Aktie (unverwässert) in % | - | 677.36 | -44.37 | 127.66 | -12.91 | 42.72 | 8.28 |
| Gewinn je Aktie (verwässert) | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 |
| Veränderung Gewinn je Aktie (verwässert) in % | - | 677.88 | -44.20 | 128.04 | -12.47 | 42.28 | 8.37 |
| Anzahl Mitarbeiter | 2’300 | 2’500 | 3’000 | 3’400 | 3’900 | 4’800 | 5’400 |
| Veränderung Anzahl Mitarbeiter in % | 6.98 | 8.70 | 20.00 | 13.33 | 14.71 | 23.08 | 12.50 |
Vertex Pharmaceuticals Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 11.02.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 30.04.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 31.07.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 29.10.2025 |
Vertex Pharmaceuticals Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 04.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 01.08.2024 |
| Hauptversammlung | Annual General Meeting | 15.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 06.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 05.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 06.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 01.08.2023 |
| Hauptversammlung | Annual General Meeting | 17.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 01.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 07.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 18.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 26.01.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.75 |
| Capital Research & Management Co. (World Investors) | 10.39 |
| Capital Research & Management Co. (World Investors) | 10.04 |
| The Vanguard Group, Inc. | 8.63 |
| Vanguard Group, Inc. (Subfiler) | 8.52 |
| State Street Corp. | 4.58 |
| Capital Research & Management Co. (Global Investors) | 3.49 |
| BlackRock Fund Advisors | 3.36 |
| Vanguard Total Stock Market ETF | 3.17 |
| American Funds Growth Fund of America | 3.14 |
| Fidelity Management & Research Co. LLC | 3.01 |
| AllianceBernstein LP | 2.86 |
| Vanguard 500 Index Fund | 2.62 |
| Geode Capital Management LLC | 2.30 |
| BlackRock Institutional Trust Co. NA | 2.23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3’000 | 3’400 | 3’900 | 4’800 | 5’400 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1.38 | 1.83 | 1.95 | 1.82 | 1.82 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4’823 | 8’133 | 9’561 | 13’235 | 14’144 |
| Summe Anlagevermögen | 3’496 | 3’618 | 3’872 | 4’916 | 8’942 |
| Summe Aktiva | 8’318 | 11’752 | 13’433 | 18’151 | 23’086 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 673 | 942 | 967 | 900 | 808 |
| Summe Fremdkapital | 2’233 | 3’065 | 3’333 | 4’238 | 5’506 |
| Summe Eigenkapital | 6’085 | 8’687 | 10’100 | 13’913 | 17’580 |
| Summe Passiva | 8’318 | 11’752 | 13’433 | 18’151 | 23’086 |
Adresse
| 50 Northern Avenue, 02210 Boston | |
| Telefon | +1 (617) 341-6100 |
| URL | http://www.vrtx.com |
Management
|
Alan M. Garber
Independent Director |
|
Amit K. Sachdev
Chief Patient Officer & Executive Vice President |
|
Bruce I. Sachs
Lead Independent Director |
|
Carmen Bozic
Chief Medical Officer & EVP-Medical Affairs |
|
Catherine Rutten
Vice President-International & Government Affairs |
|
Charles F. Wagner
Chief Financial Officer & Executive Vice President |
|
David Matthew Altshuler
Chief Scientific Officer & EVP-Global Research |
|
Diana L. McKenzie
Independent Director |
|
Edward Morrow Atkinson
Chief Technical Operations Officer & Executive VP |
|
Jeffrey M. Leiden
Executive Chairman |
|
Jennifer Schneider
Independent Director |
|
Jonathan Prim Biller
Chief Legal Officer & Executive Vice President |
|
Joy Liu
Secretary, Senior Vice President & General Counsel |
|
Kristen C. Ambrose
Chief Accounting Officer & Senior Vice President |
|
Lloyd A. Carney
Independent Director |
|
Ludovic Fenaux
Senior VP-International Commercial Operations |
|
Mark Bunnage
Senior Vice President & Head-Research |
|
Michel Lagarde
Independent Director |
|
Mike Tirozzi
Senior VP, Chief Information & Data Officer |
|
Nancy A. Thornberry
Independent Director |
|
Nia Tatsis
Chief Regulatory & Quality Officer, Executive VP |
|
Reshma Kewalramani
President, Chief Executive Officer & Director |
|
Sangeeta N. Bhatia
Independent Director |
|
Sean Daughtry
Senior Director-Analytical Sciences & Technology |
|
Stephanie Franklin
Chief Human Resources Officer & Senior VP |
|
Stuart A. Arbuckle
Chief Operating Officer & Executive Vice President |
|
Suketu P. Upadhyay
Independent Director |
|
Susie Lisa
Senior Vice President-Investor Relations |